Trials / Unknown
UnknownNCT05028218
A Clinical Study of TQB3824 in Subjects With Advanced Cancer
A Phase I Study to Evaluate the Safety and Pharmacokinetics of TQB3824 in Subjects With Advanced Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB3824 blocks function of a specific protein called Cell Division Cycle 7 (CDC7) kinase in the human body, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways. This study will evaluate the safety, tolerability and pharmacokinetics of TQB3824.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3824 tablets | TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways. |
Timeline
- Start date
- 2021-08-31
- Primary completion
- 2024-08-01
- Completion
- 2024-12-01
- First posted
- 2021-08-31
- Last updated
- 2021-09-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05028218. Inclusion in this directory is not an endorsement.